Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2020

31.05.2020 | Editorial

NUC-1031 in biliary tract cancer: from bench to bedside and back?

verfasst von: Lenka N. C. Boyd, Godefridus J. Peters, Geert Kazemier, Elisa Giovannetti

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

In preclinical models of biliary tract cancer, NUC-1031 showed less potency than gemcitabine, no correlation with potential biomarkers and only moderate additive interaction in combination with cisplatin. These findings should prompt further careful pharmacological and translational studies to better define the purported therapeutic advantage of NUC-1031 over gemcitabine. That would be a more cautious approach than the phase III clinical trial which is planning to enrol 828 patients with biliary tract tumours to compare gemcitabine/cisplatin “conventional” treatment with or without NUC-1031.
Literatur
3.
Zurück zum Zitat Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, Investigators for the ABC-02 trial (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281. https://doi.org/10.1056/NEJMoa0908721 CrossRefPubMed Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, Investigators for the ABC-02 trial (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281. https://​doi.​org/​10.​1056/​NEJMoa0908721 CrossRefPubMed
5.
Zurück zum Zitat Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Luiz Serrano Uson Junior P, Marius Nagalo B, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ (2020) Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-020-04079-z CrossRefPubMed Arora M, Bogenberger JM, Abdelrahman A, Leiting JL, Chen X, Egan JB, Kasimsetty A, Lenkiewicz E, Malasi S, Luiz Serrano Uson Junior P, Marius Nagalo B, Zhou Y, Salomao MA, Kosiorek HE, Braggio E, Barrett MT, Truty MJ, Borad MJ (2020) Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemother Pharmacol. https://​doi.​org/​10.​1007/​s00280-020-04079-z CrossRefPubMed
6.
Zurück zum Zitat Slusarczyk M, Lopez MH, Balzarini J, Mason M, Jiang WG, Blagden S, Thompson E, Ghazaly E, McGuigan C (2014) Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem 57(4):1531–1542. https://doi.org/10.1021/jm401853a CrossRefPubMed Slusarczyk M, Lopez MH, Balzarini J, Mason M, Jiang WG, Blagden S, Thompson E, Ghazaly E, McGuigan C (2014) Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development. J Med Chem 57(4):1531–1542. https://​doi.​org/​10.​1021/​jm401853a CrossRefPubMed
9.
Zurück zum Zitat Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, Frega G, Barbera MA, de Lorenzo S, Garajova I, Di Marco M, Pinna AD, Cescon M, Cucchetti A, Ercolani G, D'Errico-Grigioni A, Pantaleo MA, Biasco G, Tavolari S, G.I.CO. (Gruppo Italiano Colangiocarcinoma) (2016) Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients. Oncologist 21(5):600–607. https://doi.org/10.1634/theoncologist.2015-0356 CrossRefPubMedPubMedCentral Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, Frega G, Barbera MA, de Lorenzo S, Garajova I, Di Marco M, Pinna AD, Cescon M, Cucchetti A, Ercolani G, D'Errico-Grigioni A, Pantaleo MA, Biasco G, Tavolari S, G.I.CO. (Gruppo Italiano Colangiocarcinoma) (2016) Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients. Oncologist 21(5):600–607. https://​doi.​org/​10.​1634/​theoncologist.​2015-0356 CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Raffenne J, Nicolle R, Puleo F, Le Corre D, Boyez C, Marechal R, Emile JF, Demetter P, Bardier A, Laurent-Puig P, de Mestier L, Paradis V, Couvelard A, VanLathem JL, MacKey JR, Bachet JB, Svrcek M, Cros J (2019) hENT1 testing in pancreatic ductal adenocarcinoma: are we ready? A multimodal evaluation of hENT1 status. Cancers (Basel) 11(11):1808. https://doi.org/10.3390/cancers11111808 CrossRef Raffenne J, Nicolle R, Puleo F, Le Corre D, Boyez C, Marechal R, Emile JF, Demetter P, Bardier A, Laurent-Puig P, de Mestier L, Paradis V, Couvelard A, VanLathem JL, MacKey JR, Bachet JB, Svrcek M, Cros J (2019) hENT1 testing in pancreatic ductal adenocarcinoma: are we ready? A multimodal evaluation of hENT1 status. Cancers (Basel) 11(11):1808. https://​doi.​org/​10.​3390/​cancers11111808 CrossRef
15.
Zurück zum Zitat McNamara MG, Bridgewater JA, Palmer DH, Singh Wasan H, Ryder D, Gnanaranjan C, Ghazaly E, Jeffry Evans TR, Valle JW (2018) ABC-08: A phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue NUC-1031 in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers. JCO 36:TPS544. https://doi.org/10.1200/JCO.2018.36.4_suppl.TPS544 CrossRef McNamara MG, Bridgewater JA, Palmer DH, Singh Wasan H, Ryder D, Gnanaranjan C, Ghazaly E, Jeffry Evans TR, Valle JW (2018) ABC-08: A phase Ib, multi-centre, open-label study of a first-in-class nucleotide analogue NUC-1031 in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers. JCO 36:TPS544. https://​doi.​org/​10.​1200/​JCO.​2018.​36.​4_​suppl.​TPS544 CrossRef
16.
Zurück zum Zitat Roos E, Soer EC, Klompmaker S, Meijer LL, Besselink MG, Giovannetti E, Heger M, Kazemier G, Klumpen HJ, Takkenberg RB, Wilmink H, Wurdinger T, Dijk F, van Gulik TM, Verheij J, van de Vijver MJ (2019) Crossing borders: a systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. Crit Rev Oncol Hematol 140:8–16. https://doi.org/10.1016/j.critrevonc.2019.05.011 CrossRefPubMed Roos E, Soer EC, Klompmaker S, Meijer LL, Besselink MG, Giovannetti E, Heger M, Kazemier G, Klumpen HJ, Takkenberg RB, Wilmink H, Wurdinger T, Dijk F, van Gulik TM, Verheij J, van de Vijver MJ (2019) Crossing borders: a systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. Crit Rev Oncol Hematol 140:8–16. https://​doi.​org/​10.​1016/​j.​critrevonc.​2019.​05.​011 CrossRefPubMed
Metadaten
Titel
NUC-1031 in biliary tract cancer: from bench to bedside and back?
verfasst von
Lenka N. C. Boyd
Godefridus J. Peters
Geert Kazemier
Elisa Giovannetti
Publikationsdatum
31.05.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2020
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-020-04080-6

Weitere Artikel der Ausgabe 6/2020

Cancer Chemotherapy and Pharmacology 6/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.